Morgan Stanley Maintains Overweight on Cabaletta Bio, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Cabaletta Bio (NASDAQ:CABA) and raised the price target from $16 to $28.
November 08, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Cabaletta Bio and raised the price target from $16 to $28, indicating a positive outlook for the company.
The raised price target by Morgan Stanley indicates a positive outlook for Cabaletta Bio. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100